JP2015531606A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015531606A5 JP2015531606A5 JP2015533194A JP2015533194A JP2015531606A5 JP 2015531606 A5 JP2015531606 A5 JP 2015531606A5 JP 2015533194 A JP2015533194 A JP 2015533194A JP 2015533194 A JP2015533194 A JP 2015533194A JP 2015531606 A5 JP2015531606 A5 JP 2015531606A5
- Authority
- JP
- Japan
- Prior art keywords
- cell population
- mitochondrial
- cell
- contacting
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 15
- 210000004027 cell Anatomy 0.000 claims 14
- 230000002438 mitochondrial effect Effects 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 230000008823 permeabilization Effects 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 101150082208 DIABLO gene Proteins 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims 2
- MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 claims 1
- MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 claims 1
- MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 claims 1
- MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 claims 1
- RZCJYMOBWVJQGV-UHFFFAOYSA-N 2-naphthyloxyacetic acid Chemical compound C1=CC=CC2=CC(OCC(=O)O)=CC=C21 RZCJYMOBWVJQGV-UHFFFAOYSA-N 0.000 claims 1
- MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 claims 1
- 102000003829 Adenylate kinase 2 Human genes 0.000 claims 1
- 108090000115 Adenylate kinase 2 Proteins 0.000 claims 1
- 108010079882 Bax protein (53-86) Proteins 0.000 claims 1
- 102000018832 Cytochromes Human genes 0.000 claims 1
- 108010052832 Cytochromes Proteins 0.000 claims 1
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 claims 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 claims 1
- 101100232163 Mus musculus Htra2 gene Proteins 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 claims 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- FNEZBBILNYNQGC-UHFFFAOYSA-N methyl 2-(3,6-diamino-9h-xanthen-9-yl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C1C2=CC=C(N)C=C2OC2=CC(N)=CC=C21 FNEZBBILNYNQGC-UHFFFAOYSA-N 0.000 claims 1
- 210000001700 mitochondrial membrane Anatomy 0.000 claims 1
- 231100001143 noxa Toxicity 0.000 claims 1
- 229930191479 oligomycin Natural products 0.000 claims 1
- MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 230000000861 pro-apoptotic effect Effects 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261702967P | 2012-09-19 | 2012-09-19 | |
| US61/702,967 | 2012-09-19 | ||
| PCT/US2013/060707 WO2014047342A1 (en) | 2012-09-19 | 2013-09-19 | Dynamic bh3 profiling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018109490A Division JP6684857B2 (ja) | 2012-09-19 | 2018-06-07 | ダイナミックｂｈ３プロファイリング |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015531606A JP2015531606A (ja) | 2015-11-05 |
| JP2015531606A5 true JP2015531606A5 (enExample) | 2016-11-04 |
| JP6352924B2 JP6352924B2 (ja) | 2018-07-04 |
Family
ID=49304346
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015533194A Active JP6352924B2 (ja) | 2012-09-19 | 2013-09-19 | ダイナミックｂｈ３プロファイリング |
| JP2018109490A Active JP6684857B2 (ja) | 2012-09-19 | 2018-06-07 | ダイナミックｂｈ３プロファイリング |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018109490A Active JP6684857B2 (ja) | 2012-09-19 | 2018-06-07 | ダイナミックｂｈ３プロファイリング |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10393733B2 (enExample) |
| EP (1) | EP2898327A1 (enExample) |
| JP (2) | JP6352924B2 (enExample) |
| AU (1) | AU2013317985B2 (enExample) |
| CA (1) | CA2885230C (enExample) |
| HK (1) | HK1213046A1 (enExample) |
| WO (1) | WO2014047342A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022580A2 (en) | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
| US8221966B2 (en) | 2006-03-31 | 2012-07-17 | Dana Farber Cancer Institute | Methods of determining cellular chemosensitivity |
| WO2014047342A1 (en) | 2012-09-19 | 2014-03-27 | Dana-Farber Cancer Institute, Inc. | Dynamic bh3 profiling |
| JP2016526892A (ja) * | 2013-07-18 | 2016-09-08 | ユートロピクス ファーマシューティカルズ， インコーポレイテッド | 示差的ｂｈ３ミトコンドリアプロファイリング |
| JP6663852B2 (ja) * | 2013-09-19 | 2020-03-13 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｂｈ３プロファイリングの方法 |
| HK1247250A1 (zh) | 2015-01-12 | 2018-09-21 | Eutropics Pharmaceuticals, Inc. | 用於指导癌症治疗的内容相关的诊断测试 |
| US20180100859A1 (en) * | 2015-03-24 | 2018-04-12 | Eutropics Pharmaceuticals, Inc. | Surrogate functional biomarker for solid tumor cancer |
| JP6851978B2 (ja) | 2015-04-20 | 2021-03-31 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | ミトコンドリアプロファイリングによるアルボシジブ応答の予測 |
| EP3289094B1 (en) * | 2015-04-27 | 2024-06-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for assessing toxicity using dynamic bh3 profiling |
| JP6510075B2 (ja) | 2015-05-18 | 2019-05-08 | トレロ ファーマシューティカルズ， インコーポレイテッド | バイオアベイラビリティが高いアルボシジブプロドラッグ |
| EP3331510A4 (en) | 2015-08-03 | 2019-04-03 | Tolero Pharmaceuticals, Inc. | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER |
| US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| CA3047557A1 (en) | 2016-12-19 | 2018-06-28 | Tolero Pharmaceuticals, Inc. | Profiling peptides and methods for sensitivity profiling |
| WO2018134254A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| EP3385715A1 (en) | 2017-04-04 | 2018-10-10 | Medizinische Hochschule Hannover | Analytical process for predicting the therapeutic effect of bh3 mimetics |
| WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
| US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| WO2020176689A1 (en) * | 2019-02-26 | 2020-09-03 | Dana-Farber Cancer Institute, Inc. | Live cell imaging dynamic bh3 profiling |
| US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
| EP4306953A1 (en) | 2022-07-12 | 2024-01-17 | Fundació Institut de Bioenginyeria de Catalunya (IBEC) | Real-time tracking of apoptosis |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5674980A (en) | 1989-12-21 | 1997-10-07 | Biogen Inc | Fusion protein comprising tat-derived transport moiety |
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| AU705563B2 (en) | 1995-07-28 | 1999-05-27 | Marie Curie Cancer Care | Transport proteins and their uses |
| JP3295431B2 (ja) | 1995-10-24 | 2002-06-24 | サングスタット メディカル コーポレイション | 抗アルファ−ガラクトシルスクリーニング技術 |
| US5965703A (en) | 1996-09-20 | 1999-10-12 | Idun Pharmaceuticals | Human bad polypeptides, encoding nucleic acids and methods of use |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| WO1999014321A1 (en) | 1997-09-17 | 1999-03-25 | The Walter And Eliza Hall Institute Of Medical Research | Novel therapeutic molecules |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| EP1210098A1 (en) | 1999-04-07 | 2002-06-05 | Thomas Jefferson University | Enhancement of peptide cellular uptake |
| WO2001012661A2 (en) | 1999-08-16 | 2001-02-22 | The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Healthand Human Services, The National Institutes Of Health | RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS |
| WO2002020568A2 (en) | 2000-09-06 | 2002-03-14 | Abbott Laboratories | Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins |
| US20020115613A1 (en) | 2001-02-16 | 2002-08-22 | Kumar M. Vijay | Treatment of prostate cancer |
| WO2003040168A2 (en) | 2001-11-06 | 2003-05-15 | Enanta Pharmaceuticals, Inc. | Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype |
| JP2005518393A (ja) | 2001-12-21 | 2005-06-23 | アリアス リサーチ、インコーポレイテッド | 個別化抗癌抗体 |
| WO2004022580A2 (en) | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
| US20070032417A1 (en) | 2002-12-24 | 2007-02-08 | Walter And Eliza Hall Institute Of Medical Research | Peptides and therapeutic uses thereof |
| WO2004083405A2 (en) | 2003-03-19 | 2004-09-30 | Alfa Wassermann, Inc. | Separation and accumulation of subcellular components, and proteins derived therefrom |
| PT2332968T (pt) | 2003-11-05 | 2016-08-17 | Harvard College | Péptidos alfa-helicoidais adequados para a activação ou inibição da morte celular |
| WO2006069186A2 (en) * | 2004-12-22 | 2006-06-29 | The Ohio State Research Foundation | Small molecule bcl-xl/bcl-2 binding inhibitors |
| JP2005130867A (ja) | 2005-02-16 | 2005-05-26 | Mitokor | ミトコンドリア内カルシウムを使用するスクリーニングアッセイ |
| WO2006099667A1 (en) | 2005-03-21 | 2006-09-28 | The Walter And Eliza Hall Institute Of Medical Research | Prophylactic and therapeutic agents and uses therefor |
| WO2007016254A2 (en) | 2005-07-27 | 2007-02-08 | The Board Of Trustees Of The University Of Arkansas | Antineoplastic activities of ellipticine and its derivatives |
| US8221966B2 (en) | 2006-03-31 | 2012-07-17 | Dana Farber Cancer Institute | Methods of determining cellular chemosensitivity |
| US8518635B2 (en) | 2006-06-12 | 2013-08-27 | The J. David Gladstone Institutes | Regulation of protein activity by reversible acetylation |
| KR100786759B1 (ko) | 2006-07-07 | 2007-12-18 | 김현기 | Ｈｃｃｒ-1을 포함하는 유방암 예후 마커 및 비만 유도조성물 |
| US9360473B2 (en) * | 2006-08-16 | 2016-06-07 | Eutropics Pharmaceuticals, Inc. | Assay system to identify therapeutic agents |
| WO2008152405A2 (en) | 2007-06-15 | 2008-12-18 | The Queen's University Of Belfast | Protein complexes comprising bh3 peptides and voltage dependent anion channel (vdac) peptides as well as uses thereof for the treatment of proliferative diseases |
| KR20100074177A (ko) | 2007-09-10 | 2010-07-01 | 유니버시티 오브 매사추세츠 | 미토콘드리아-표적화된 항-종양 물질 |
| CA2700925C (en) | 2007-09-26 | 2016-08-23 | Dana Farber Cancer Institute | Methods and compositions for modulating bcl-2 family polypeptides |
| JP2009240173A (ja) | 2008-03-28 | 2009-10-22 | Univ Of Tokushima | パーキン蛋白の新規糖化因子 |
| EA026732B1 (ru) | 2009-06-11 | 2017-05-31 | Минерва Байотекнолоджиз Корпорейшн | Способы культивирования стволовых клеток и клеток-предшественников |
| WO2010147961A1 (en) | 2009-06-15 | 2010-12-23 | Precision Therapeutics, Inc. | Methods and markers for predicting responses to chemotherapy |
| US20130122492A1 (en) | 2011-11-14 | 2013-05-16 | Kellbenx Inc. | Detection, isolation and analysis of rare cells in biological fluids |
| CN107315088A (zh) | 2012-05-10 | 2017-11-03 | 尤特罗皮克斯制药股份有限公司 | 对癌症的代理功能性诊断测试 |
| US20150322479A1 (en) | 2012-06-20 | 2015-11-12 | Cytospan Technologies Corporation | Apparatus and method for quantification of replicative lifespan and observation of senescene |
| WO2014047342A1 (en) | 2012-09-19 | 2014-03-27 | Dana-Farber Cancer Institute, Inc. | Dynamic bh3 profiling |
| JP6327662B2 (ja) | 2012-09-26 | 2018-05-23 | 学校法人藤田学園 | 細胞表面タンパクを抗原とする抗体を測定する方法 |
| JP2016526892A (ja) | 2013-07-18 | 2016-09-08 | ユートロピクス ファーマシューティカルズ， インコーポレイテッド | 示差的ｂｈ３ミトコンドリアプロファイリング |
| JP6663852B2 (ja) | 2013-09-19 | 2020-03-13 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｂｈ３プロファイリングの方法 |
| EP3289094B1 (en) | 2015-04-27 | 2024-06-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for assessing toxicity using dynamic bh3 profiling |
| WO2017007858A1 (en) | 2015-07-06 | 2017-01-12 | Whitehead Institute For Biomedical Research | Methods and compositions relating to proteasome inhibitor resistance |
| WO2020176689A1 (en) | 2019-02-26 | 2020-09-03 | Dana-Farber Cancer Institute, Inc. | Live cell imaging dynamic bh3 profiling |
-
2013
- 2013-09-19 WO PCT/US2013/060707 patent/WO2014047342A1/en not_active Ceased
- 2013-09-19 US US14/429,272 patent/US10393733B2/en active Active
- 2013-09-19 JP JP2015533194A patent/JP6352924B2/ja active Active
- 2013-09-19 CA CA2885230A patent/CA2885230C/en active Active
- 2013-09-19 EP EP13773484.4A patent/EP2898327A1/en active Pending
- 2013-09-19 HK HK16100721.8A patent/HK1213046A1/zh unknown
- 2013-09-19 AU AU2013317985A patent/AU2013317985B2/en active Active
-
2018
- 2018-06-07 JP JP2018109490A patent/JP6684857B2/ja active Active
-
2019
- 2019-07-11 US US16/508,459 patent/US11815508B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015531606A5 (enExample) | ||
| JP2016536005A5 (enExample) | ||
| Sun et al. | Peptide-based imaging agents for cancer detection | |
| JP2018171062A5 (enExample) | ||
| BR112016004437A2 (pt) | métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit | |
| MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
| CO2022008396A2 (es) | Receptores tcr de prame | |
| MX2019000935A (es) | Metodos para cuantificar anticuerpos individuales de una mezcla. | |
| PE20190845A1 (es) | Metodos para determinar resistencia a terapia de receptor de androgeno | |
| MX2015012824A (es) | Antigenos recombinantes ns3 del vhc y mutantes de los mismos para la deteccion mejorada de anticuerpos. | |
| Maslyanskiy et al. | Anti‐hnRNP B1 (RA33) Autoantibodies Are Associated with the Clinical Phenotype in Russian Patients with Rheumatoid Arthritis and Systemic Sclerosis | |
| JP2017534851A5 (enExample) | ||
| Leung et al. | Ovarian cancer biomarkers: current state and future implications from high-throughput technologies | |
| Argyropoulos et al. | Forecasting economic activity from yield curve factors | |
| Beauchemin et al. | Assay development and high-throughput screening for inhibitors of Kaposi’s sarcoma–associated herpesvirus N-terminal latency-associated nuclear antigen binding to nucleosomes | |
| JP2017536104A5 (enExample) | ||
| JP2018504903A5 (enExample) | ||
| Di Perna et al. | The physical interaction of Mcm10 with Cdc45 modulates their DNA-binding properties | |
| JP2015529211A5 (enExample) | ||
| Kanaba et al. | Microtubule-binding sites of the CH domain of EB1 and its autoinhibition revealed by NMR | |
| JP2017037014A5 (enExample) | ||
| EP3315613A3 (en) | Methods and kits for diagnosing or assessing the risk of cervical cancer | |
| Çitil et al. | Evaluation of Patients who were Prediagnosed As Cystic Echinococcosis by Using Indirect Haemagglutination Test (IHA) Technique in Adıyaman | |
| Shi et al. | PWWP3A disrupts the assembly of VISA/MAVS signalosome to inhibit innate immune response against RNA viruses | |
| MX391000B (es) | Uso de la combinación de biomarcadores y anticuerpos séricos para el diagnóstico de tuberculosis humana. |